SCHEMBL3570018

SCHEMBL3570018

CN1CCN(c2ccc(N/C=C3\C(=O)NCc4ccc(Br)cc43)cc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
MAPK1 P28482 2/20 0.39
PDGFRB P09619 1/20 0.39
MEN1 O00255 1/20 0.39
APAF1 O14727 1/20 0.39
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CDK4 P11802 2/20 0.38
CCND1 P24385 2/20 0.38
CDK2 P24941 1/20 0.38
EGFR P00533 1/20 0.37
KDR P35968 1/20 0.37
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
TSHR P16473 1/20 0.36
FLT3 P36888 1/20 0.36
MAP2K1 Q02750 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3570020 1.00 MAPKAPK2 (0.40) MAPKAPK2SMN1; SMN2MAPK1PDGFRBMEN1
SCHEMBL3569161 0.92 MAPKAPK2 (0.40) MAPKAPK2SMN1; SMN2MAPK1PDGFRBMEN1
SCHEMBL3569159 0.92 MAPKAPK2 (0.40) MAPKAPK2SMN1; SMN2MAPK1PDGFRBMEN1
SCHEMBL14472751 0.88 ASIC3 (0.36) SMN1; SMN2MAPK1EGFRNPC1RAB9A
SCHEMBL3568900 0.85 NPC1 (0.42) SMN1; SMN2MEN1OPRM1OPRD1KMT2A
SCHEMBL3568903 0.85 NPC1 (0.42) SMN1; SMN2MEN1OPRM1OPRD1KMT2A
SCHEMBL3660969 0.84 PDGFRB (0.44) MAPKAPK2SMN1; SMN2MAPK1PDGFRBMEN1
SCHEMBL3660965 0.84 PDGFRB (0.44) MAPKAPK2SMN1; SMN2MAPK1PDGFRBMEN1
SCHEMBL3562396 0.84 PDGFRB (0.44) MAPKAPK2SMN1; SMN2MAPK1PDGFRBMEN1
SCHEMBL3562399 0.84 PDGFRB (0.44) MAPKAPK2SMN1; SMN2MAPK1PDGFRBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US claimed
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US disclosed
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US disclosed
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US disclosed
EP-1963273-A2 SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2008-09-03 EP disclosed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US disclosed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US disclosed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US disclosed
WO-2007075783-A2 SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR WYETH (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof SULT1E1, RECQL, HAX1 MAPKAPK2 4491/4885SMN1; SMN2 3642/4885MAPK1 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.